Company
KaNDy Therapeutics
- Status
- Acquiredas of 2026-09-23Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- United Kingdom
Claim, correct or request removal
Record updated 28 September 2026
About
KaNDy Therapeutics was a UK based clinical-stage company focused on developing NT-814, a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS). KaNDy was sold to Bayer Pharmaceuticals in 2020 for $425M up front and additional consideration in the form of milestone payments.
About the company
- Status notes
- KaNDy was sold to Bayer Pharmaceuticals in 2020 for $425M up front and additional consideration in the form of milestone payments.
Products
- Web
- NT-814
Exit
- Acquisition
- $425M, 2020$425M up front and additional consideration in the form of milestone payments
Loading relationship preview